The Relationship between Abnormal Screening Bone Scintigraphy and Bone Metastasis in Breast Cancer Patients.
- Author:
Jeong Eon LEE
1
;
Hyuk Jai SHIN
;
Wonshik HAN
;
Seok Won KIM
;
Kyoung Sik PARK
;
Sung Won KIM
;
Seung Keun OH
;
Yeo Kyu YOUN
;
Kuk Jin CHOE
;
Dong Young NOH
Author Information
- Publication Type:Original Article
- Keywords: Breast cancer; Bone scintigraphy; Bone metastasis; Lymphatic vessel invasion; C-erb-B2; AJCC staging system
- MeSH: Breast Neoplasms*; Breast*; Classification; Diagnosis; Estrogens; Follow-Up Studies; Humans; Incidence; Lymphatic Vessels; Mass Screening*; Mastectomy; Mastectomy, Segmental; Neoplasm Metastasis*; Radionuclide Imaging*; Receptor, Epidermal Growth Factor; Receptors, Progesterone; Retrospective Studies; Ribs; Seoul; Skull; Spine; Sternum
- From:Journal of Breast Cancer 2005;8(1):56-61
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: In this study we evaluated the significance of false positive screening bone scintigraphy (BS) in primary invasive breast cancer patients. Lymphatic vessel invasion (LVI), estrogen receptor (ER), progesterone receptor (PR), nuclear grade, histology grade, epidermal growth factor receptor (EGFR) and C-erb-B2 values were examined in terms of their abilities to predict the accuracy of abnormal BS. We also examined the incidence of bone metastasis in primary invasive breast cancer patients according to the 1988 and 2003 AJCC classifications. METHODS: A retrospective review was performed on 2,044 primary invasive breast cancer patients that had received BS screening, and who were treated by mastectomy or breast conserving surgery at the Seoul National University Hospital between Jan 1995 and Jul 2003. Abnormal screening BS results were divided into "less suspicious" and "highly suspicious" groups. Patient's stages according to the 1988 AJCC classification were reclassified according to the 2003 AJCC classification. Bone metastasis was confirmed by further radiological examination or follow-up BS. All statistical analyses were two-tailed. RESULTS: The incidences of bone metastasis and an abnormal screening BS result were 1.7% (35/2,044) and 13.8% (283/2,044), respectively. The false positive rate of screening BS was 87.6% (248/283). LVI was the only significant predictive factor of bone metastasis in 283 of the abnormal BS patients (p <.001). c-erb-B2 showed no significance to predict bone metastasis in the "less suspicious" group, but was Bone is the most common site of distant metastasis in invasive breast cancer at the time of primary diagnosis. The vertebrae are the most common sites of bone metastasis and the ribs, skull, sternum and proximal long bones are also frequently involved. Bone metastases affect 8% of patients marginally significant in the "highly suspicious" group (p = .046). ER, PR, nuclear grade, histology grade, and EGFR showed no significance in terms of predicting the accuracy of an abnormal BS result. The incidences of bone metastasis were 0.6, 1.3 and 7.6% in stages I, II and III, respectively, according to the 1988 AJCC classification, while these incidences were 0.6, 0.7 and 5.8% according to the 2003 AJCC classification. CONCLUSION: The use of screening bone scintigraphy as a routine screening test is hard to justify due to its high false positive rate. LVI may be a useful factor in that it predicts the accuracy of an abnormal BS result. The incidences of bone metastasis in stages II and III were lower for the 2003 AJCC staging system.
